• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy.

作者信息

Mital Rohan, Cartron Alexander M, Trinidad John C, Spaccarelli Natalie, Gibbons-Fideler I-Sanna, Kaffenberger Benjamin H, Chung Catherine G

机构信息

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland.

出版信息

JAAD Case Rep. 2022 Nov 24;31:124-127. doi: 10.1016/j.jdcr.2022.11.020. eCollection 2023 Jan.

DOI:10.1016/j.jdcr.2022.11.020
PMID:36583144
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9792734/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b284/9792734/d17d465b6aab/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b284/9792734/ce4cd1a57d55/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b284/9792734/4cbc8d616ce7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b284/9792734/d17d465b6aab/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b284/9792734/ce4cd1a57d55/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b284/9792734/4cbc8d616ce7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b284/9792734/d17d465b6aab/gr3.jpg

相似文献

1
Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy.程序性细胞死亡蛋白1抑制剂治疗背景下的新型皮肤疹
JAAD Case Rep. 2022 Nov 24;31:124-127. doi: 10.1016/j.jdcr.2022.11.020. eCollection 2023 Jan.
2
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.与程序性细胞死亡蛋白1抑制剂治疗相关的皮肤不良反应的发作时间。
JAMA Dermatol. 2018 Sep 1;154(9):1057-1061. doi: 10.1001/jamadermatol.2018.1912.
3
Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.由抗程序性细胞死亡蛋白1（PD-1）和抗程序性细胞死亡配体1（PD-L1）免疫疗法引起的多种皮肤不良反应：临床特征与管理
Ther Adv Med Oncol. 2018 Jan 22;10:1758834017751634. doi: 10.1177/1758834017751634. eCollection 2018.
4
[Risk Factors for Anti-PD1 Antibody-Induced Skin Eruptions].[抗PD1抗体诱导的皮肤皮疹的危险因素]
Gan To Kagaku Ryoho. 2020 Aug;47(8):1189-1192.
5
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.抗程序性细胞死亡蛋白1和抗程序性细胞死亡配体1免疫治疗所致苔藓样皮肤黏膜疹的临床和组织学特征
JAMA Dermatol. 2016 Oct 1;152(10):1128-1136. doi: 10.1001/jamadermatol.2016.2226.
6
Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.抗程序性细胞死亡蛋白 1 治疗相关的亚急性皮肤型狼疮和皮肌炎。
Br J Dermatol. 2019 Sep;181(3):580-583. doi: 10.1111/bjd.17245. Epub 2018 Dec 10.
7
Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.抗程序性细胞死亡蛋白-1 治疗的皮肤不良反应的特征及预后意义。
J Korean Med Sci. 2019 Jul 8;34(26):e186. doi: 10.3346/jkms.2019.34.e186.
8
Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response.帕博利珠单抗诱导的非小细胞肺癌（NSCLC）患者扁平苔藓与治疗反应相关
Cureus. 2022 Nov 13;14(11):e31454. doi: 10.7759/cureus.31454. eCollection 2022 Nov.
9
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.晚期肺癌的联合化疗和程序性死亡受体 1/程序性死亡配体 1 抑制剂治疗的毒性管理。
Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 Feb 4.
10
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).术前 PD1 检查点阻断和核因子κB 受体激活剂配体（RANKL）抑制在非小细胞肺癌（NSCLC）中的药效学：一项多中心、开放标签、1B/2 期、转化试验（POPCORN）的研究方案。
Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x.

引用本文的文献

1
Consistently Reproducible Fixed Drug-induced Urticaria in a Patient with Metastatic Melanoma Under Immunotherapy.免疫治疗下转移性黑色素瘤患者持续可重复出现的固定性药疹性荨麻疹
Acta Derm Venereol. 2025 May 20;105:adv43652. doi: 10.2340/actadv.v105.43652.

本文引用的文献

1
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.免疫检查点抑制剂治疗的皮肤毒性：组织病理学特征综述。
J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. doi: 10.1016/j.jaad.2020.04.105. Epub 2020 Apr 29.
2
Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.抗 PD-1 治疗的皮肤不良反应——系统评价。
J Am Acad Dermatol. 2020 Nov;83(5):1415-1424. doi: 10.1016/j.jaad.2020.04.058. Epub 2020 Apr 19.
3
Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.
免疫检查点抑制剂的皮肤毒性：皮肤科医生的作用。
Yale J Biol Med. 2020 Mar 27;93(1):123-132. eCollection 2020 Mar.
4
Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report.转移性肺癌患者使用纳武利尤单抗治疗后出现带状疱疹样肉芽肿性皮炎：一例报告。
Thorac Cancer. 2020 May;11(5):1330-1333. doi: 10.1111/1759-7714.13377. Epub 2020 Mar 5.
5
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
6
An unusual skin reaction in uveal melanoma during treatment with nivolumab: extragenital lichen sclerosus.在接受纳武利尤单抗治疗期间，葡萄膜黑色素瘤出现一种不常见的皮肤反应：外阴硬化性苔藓。
Anticancer Drugs. 2019 Oct;30(9):969-972. doi: 10.1097/CAD.0000000000000819.
7
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.免疫检查点抑制剂治疗相关炎症性皮疹：毒性分层的单机构回顾性分析及其对治疗的影响。
J Am Acad Dermatol. 2019 Apr;80(4):990-997. doi: 10.1016/j.jaad.2018.10.062. Epub 2018 Nov 3.
8
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.
9
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.用于癌症免疫治疗的PD-1和PD-L1检查点信号抑制：机制、联合应用及临床结果
Front Pharmacol. 2017 Aug 23;8:561. doi: 10.3389/fphar.2017.00561. eCollection 2017.
10
Postherpetic Granulomatous Dermatitis in a Man Treated With Nivolumab.接受纳武单抗治疗的男性患者发生的疱疹后肉芽肿性皮炎
Actas Dermosifiliogr. 2017 Oct;108(8):783-784. doi: 10.1016/j.ad.2017.02.016. Epub 2017 May 19.